Xenetic Biosciences, Inc.

NasdaqCM XBIO

Xenetic Biosciences, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -4.08 M

Xenetic Biosciences, Inc. Net Income is USD -4.08 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 4.89% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Xenetic Biosciences, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -4.29 M, a 36.81% change year over year.
Xenetic Biosciences, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -6.78 M, a -35.60% change year over year.
Xenetic Biosciences, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -5.00 M, a 53.94% change year over year.
Xenetic Biosciences, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -10.86 M, a 17.97% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqCM: XBIO

Xenetic Biosciences, Inc.

CEO	Mr. James F. Parslow
IPO Date	June 30, 2016
Location	United States
Headquarters	40 Speen Street
Employees	4
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Key trends

Past 5 years